Surveyed Experts Indicate That Xarelto Has Advantages Over Lovenox in the Treatment of Venous Thromboembolism in Medically Ill Patients
Posted on: Monday, 23 March 2009, 08:00 CDT
Xarelto Will Earn Decision Resources' Clinical Gold Standard Status for VTE Prophylaxis in 2012, According to a New Report from Decision Resources
The new report entitled Venous Thromboembolism Prophylaxis in Medically Ill Patients: Significant Opportunity Awaits Therapies Offering Improved Efficacy finds that an orally available therapy for VTE prophylaxis in medically ill patients would earn a 65 percent patient share in
In 2008, Decision Resources' proprietary clinical gold standard for VTE prophylaxis in medically ill patients was GlaxoSmithKline's Arixtra, owing largely to its efficacy. Based on available data and expert opinion, Xarelto will earn gold standard status for VTE prophylaxis in medically ill patients in 2012, following its approval for the indication in 2011.
"Xarelto has competitive advantages over Arixtra in terms of delivery and safety," said Decision Resources Analyst
About the Report
Venous Thromboembolism Prophylaxis in Medically Ill Patients: Significant Opportunity Awaits Therapies Offering Improved Efficacy is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall 781-296-2597 781-296-2563 ccomfort@dresources.com emarshall@dresources.comSOURCE Decision Resources
Source: PR Newswire
Related Articles
- Patient Safety and Medical Liability Reform Subcommittee Meeting
- Guidelines For Use Of Patient Records In Medical Research
- Neuropathy Patients, Doctors and Medical Professionals Rally in Sacramento to Demand Access to Lifesaving Medical Treatments
- Patient Side Point-of-Care Testing in the Emergency Department Enables Quicker Treatment Decisions for Patients With Chest Pain
- As National Patient Safety Awareness Week Begins - AMA, AARP Offer Tips, Resources on Maximizing Patient-Physician Relationship
- Carondelet Health Network Selects Patient Care Technology Systems' Automatic Tracking Software; Software Will Track Patients and Mobile Medical Equipment in Emergency Department and Operating Rooms
- Patient Advocacy and Medical Professional Coalition Applauds FDA Warning Letters but Urges Greater Enforcement
- With a Large Patient Population, High Medical Need, and a Difficult Development Path, the Sepsis Drug Market is Commercially Attractive but Risky
- Soil Change, Soil Survey, and Natural Resources Decision Making: A Blueprint for Action
- Impact of a Negative Evaluation for Underlying Coronary Artery Disease on One-Year Resource Utilization for Patients Admitted With Potential Acute Coronary Syndromes
 |
 |
User Comments (0)
RSS Feeds